评估单独使用羟氯喹或联合使用阿奇霉素在重症监护病房治疗的 2019 年冠状病毒病（COVID-19）感染患者的 QT 间期。
Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
机构信息
Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Service d'électrophysiologie et de Stimulation Cardiaque, Université de Lyon, Lyon, France.
Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Centre de Référence National des Troubles du Rythme Cardiaque d'origine Héréditaire, Lyon, France.
出版信息
JAMA Cardiol. 2020 Sep 1;5(9):1067-1069. doi: 10.1001/jamacardio.2020.1787.
Abstract
This case series assesses QT intervals for French patients with coronavirus disease 2019 (COVID-19) treated with hydroxychloroquine alone or in combination with azithromycin.
摘要
本病例系列评估了单独使用羟氯喹或联合使用羟氯喹和阿奇霉素治疗的法国 COVID-19 患者的 QT 间期。
相似文献
1
Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
JAMA Cardiol. 2020 Sep 1;5(9):1067-1069. doi: 10.1001/jamacardio.2020.1787.
2
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
3
QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Arq Bras Cardiol. 2020 Jun;114(6):1061-1066. doi: 10.36660/abc.20200389. Epub 2020 Jul 3.
4
QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
Heart Rhythm. 2020 Sep;17(9):1425-1433. doi: 10.1016/j.hrthm.2020.05.014. Epub 2020 May 12.
5
Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
J Am Heart Assoc. 2020 Jun 16;9(12):e017144. doi: 10.1161/JAHA.120.017144. Epub 2020 May 28.
6
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.
7
Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
J Clin Pharmacol. 2020 Jul;60(7):808-814. doi: 10.1002/jcph.1646. Epub 2020 May 20.
8
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
PLoS One. 2020 Aug 13;15(8):e0237693. doi: 10.1371/journal.pone.0237693. eCollection 2020.
9
Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.
Nephrol Dial Transplant. 2020 Aug 1;35(8):1346-1353. doi: 10.1093/ndt/gfaa191.
10
Acute meningoencephalitis in a patient with COVID-19.
Rev Neurol (Paris). 2020 Jun;176(6):519-521. doi: 10.1016/j.neurol.2020.04.014. Epub 2020 May 11.
引用本文的文献
1
Cardiac findings in a phase II double-blind randomized placebo-controlled trial of combination therapy (HAZDPac) to treat COVID-19 patients.
BMC Cardiovasc Disord. 2024 Dec 19;24(1):710. doi: 10.1186/s12872-024-04376-y.
2
Hydroxychloroquine-azithromycin, doubase C, and QTc prolongation in congolese patients with COVID-19: Myth or reality?
World J Virol. 2024 Jun 25;13(2):90668. doi: 10.5501/wjv.v13.i2.90668.
3
Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.
J Community Hosp Intern Med Perspect. 2024 Mar 4;14(2):58-66. doi: 10.55729/2000-9666.1308. eCollection 2024.
4
Hydroxychloroquine, QTc prolongation and risk of torsades de pointes.
Arch Med Sci Atheroscler Dis. 2023 Aug 17;8:e75-e80. doi: 10.5114/amsad/169982. eCollection 2023.
5
Outcomes of critically ill COVID-19 patients boarding in the emergency department of a tertiary care center in a developing country: a retrospective cohort study.
Int J Emerg Med. 2023 Oct 13;16(1):73. doi: 10.1186/s12245-023-00551-8.
6
The Effect of Hydroxychloroquine on In-Hospital Mortality in COVID-19.
HCA Healthc J Med. 2020 Nov 28;1:425-431. doi: 10.36518/2689-0216.1169. eCollection 2020.
7
Characterization of adverse events to hydroxychloroquine, ivermectin, azithromycin and tocilizumab in patients hospitalized due to COVID-19 in a Peruvian Social Health Insurance hospital.
Rev Peru Med Exp Salud Publica. 2023 Jan-Mar;40(1):16-24. doi: 10.17843/rpmesp.2023.401.11563. Epub 2023 Jun 23.
8
Has COVID-19 changed the spectrum of arrhythmias and the incidence of sudden cardiac death?
Herz. 2023 Jun;48(3):212-217. doi: 10.1007/s00059-023-05186-2. Epub 2023 Jun 5.
9
Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients.
Medicina (Kaunas). 2023 Apr 29;59(5):863. doi: 10.3390/medicina59050863.
10
Microfluidic Organ-Chips and Stem Cell Models in the Fight Against COVID-19.
Circ Res. 2023 May 12;132(10):1405-1424. doi: 10.1161/CIRCRESAHA.122.321877. Epub 2023 May 11.
本文引用的文献
1
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
Ann Intern Med. 2020 Jun 2;172(11):754-755. doi: 10.7326/M20-1334. Epub 2020 Mar 31.
2
Race to find COVID-19 treatments accelerates.
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
3
Covid-19: six million doses of hydroxychloroquine donated to US despite lack of evidence.
BMJ. 2020 Mar 23;368:m1166. doi: 10.1136/bmj.m1166.
4
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
5
Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Curr Clin Pharmacol. 2017;12(4):210-222. doi: 10.2174/1574884713666180223123947.
6
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.
Circulation. 2010 Mar 2;121(8):1047-60. doi: 10.1161/CIRCULATIONAHA.109.192704. Epub 2010 Feb 8.
Zotero 插件